fda statement bpc-157 not approved fda.gov An advisory panel voted yes on today. Here is the honest version. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to BPC-157 FDA Approval Status: Is

Source quality is the number one predictor of results

The Journal of Applied Physiology shows that a BPC-157 dosage is highly stable, easily dissolved in water, and doesnt need a carrier for its application

A patient at a 0.50 mg maintenance dose draws 50 units per week about 10 weekly doses per vial

Long-term use safety Evidence for long-term use: Studied for decades Safe for months to years No tolerance development Benefits maintained Cycling not necessary: Can use continuously No downregulation Some cycle for cost reasons Not required for safety How long to use: Minimum: 8-12 weeks (see results) Common: 3-6 months initially Long-term: Many use 6-12+ months Maintenance: 2-3x weekly ongoing Sourcing quality 50mg GHK-Cu Finding effective products ensures results

When a patient receives both a vaccine and a therapeutic injection at the same visit, both administration codes are billable

The free model supports accessibility, ensuring that accurate math is available to all researchers regardless of budget